Selpercatinib is the first drug from Loxo’s pipeline that Lilly has brought to market. Prior to the acquisition, Loxo won approval of Vitrakvi, which targets a different genetic mutation and is sold by Bayer AG. Flashpoint Batley: Anti-racism protesters hold rally against… Flair also analysed dozens of open letters published by alumnae of private schools...